CORDIS
EU research results

CORDIS

English EN
EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells

EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells

Objective

EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells (iPSC). Significant progress towards this aim has been made by EBiSC1; further resources, however, are required to ensure self-sustainability. Key partners of EBiSC1 who have delivered major assets of the current bank, join efforts to establish EBiSC2 as self-sustainable, central bank.
Based on a gap analysis of the EBiSC1 endeavours towards sustainability, and focussing on user demand, scientific excellence and productivity, EBiSC2 will deploy a business strategy for a sustainable, non-for-profit bank providing access to disease-relevant and quality-controlled iPSCs, along with comprehensive data and freedom to operate for academic and commercial use. To meet evolving requirements from industry and academia, the cell catalogue will be constantly enriched through on-demand generation of new iPSC lines, including gene-edited lines and isogenic controls, iPSC-derived and progenitor cells. EBiSC2 will distribute cell lines and develop a range of additional cell services (incl. screening panels of disease-relevant iPSC and control lines in ready-to-use-formats) to extend its offer, while reducing operational costs through state-of-the-art upscaling and automation enabling bulk production of standardised high-quality cells. Proof-of-concept studies performed jointly by academia and industry will demonstrate the reliability and robustness of the lines for disease modelling and screening and enrich the EBiSC2 catalogue with extensive data.
To bundle resources, EBiSC2 focuses on collaboration with iPSC programmes and aims to serve as central hub for EU-funded projects to bank their iPSC lines, and thus, enable long-term access by the research community to the results of European investments.

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Address

Hansastrasse 27c
80686 Munchen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 463 250

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

JANSSEN PHARMACEUTICA NV

Belgium

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 999 990

Department of Health england

United Kingdom

EU Contribution

€ 300 208

BIONEER A/S

Denmark

EU Contribution

€ 374 625

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 236 575

ARTTIC

France

EU Contribution

€ 225 000

Bayer

Germany

Eli Lilly and Company Limited

United Kingdom

H. LUNDBECK AS

Denmark

NOVO NORDISK A/S

Denmark

UCB BIOPHARMA SPRL

Belgium

PFIZER LIMITED

United Kingdom

TAKEDA DEVELOPMENT CENTRE EUROPE LTD.

United Kingdom

FUJIFILM CELLULAR DYNAMICS INC

United States

INSTITUT DE RECHERCHES SERVIER

France

Project information

Grant agreement ID: 821362

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    31 August 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 8 872 547,75

  • EU contribution

    € 4 599 648

Coordinated by:

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany